---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-079749"
form_type: "8-K"
ticker: "PSTV"
cik: "0001095981"
company_name: "PLUS THERAPEUTICS, INC."
filed_at: "2025-05-30T23:59:59+00:00"
generated_at: "2026-05-20T04:02:30.720234+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Plus Therapeutics Q1 net loss $17.4M; cash jumps to $9.9M on $15M financing and grants

## Summary
- Cash balance $9.9M at Mar 31, 2025 vs $0.1M at Dec 31, 2024; raised $15M private placement and $2M grant advance.
- Net loss $17.4M ($1.19/share) vs $3.3M ($0.75/share) in Q1 2024; operating loss $3.5M vs $3.3M.
- Completed ReSPECT-LM Phase 1 dose trial; FDA Orphan Drug Designation for REYOBIQ for leptomeningeal metastases in lung cancer.
- Published Phase 1 REYOBIQ data in Nature Communications: >100 Gy dose group median OS 17 months, double standard of care.
- Added board member Kyle Guse; management hires: Dr. Rosol (CDO), Bradley (CNSide President), Stein (Medical Director).

## SEC filing metadata
- accession: 0000950170-25-079749
- form_type: 8-K
- ticker: PSTV
- cik: 0001095981
- company_name: PLUS THERAPEUTICS, INC.
- filed_at: 2025-05-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1095981/000095017025079749/0000950170-25-079749-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1095981/000095017025079749/pstv-20250530.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-079749
- JSON: https://secwatch.observer/filing/0000950170-25-079749.json
- Plain text: https://secwatch.observer/filing/0000950170-25-079749.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.